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Abstract: Bile sequestrants have been used for almost 50 years to lower low density lipoprotein 
cholesterol (LDL-C). The advent of colesevelam in 2000 provided a more tolerable add-on 
LDL-C-lowering agent with an excellent safety record and with likely beneﬁ  t for coronary heart 
disease events. Colesevelam lowers LDL-C approximately 15%, and has an additive effect when 
combined with statin or non-statin lipid-modifying agents. It also tends to increase triglyceride 
levels. The discovery that bile sequestrants also lower glucose levels led to deﬁ  nitive large-scale 
clinical trials testing the effect of colesevelam as a dual antihyperglycemic agent with LDL-C-
lowering properties in type 2 diabetic subjects on metformin-, sulfonylurea- or insulin-based 
therapy with inadequate glycemic control. Colesevelam was found to lower hemoglobin A1c 
(HbA1c) by approximately 0.5% compared to placebo over the 16- to 26-week period, and had 
similar effects on the lipid proﬁ  le in these diabetic subjects, as had previously been demonstrated 
in non-diabetic individuals. Colesevelam was well tolerated, with constipation being the most 
common adverse effect, and did not cause weight gain or excessive hypoglycemia. Colesevelam 
thus combines antihyperglycemic action with LDL-C-lowering properties, and should be useful 
in the management of type 2 diabetes.
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Introduction
Evidence indicates that effective treatment of hyperglycemia, and dyslipidemia 
ameliorates the occurrence and severity of the vascular complications of type 2 
diabetes.1–3 At a time where diabetes prevalence is expanding signiﬁ  cantly world-wide, 
it is critical that every effort be made to achieve recommended treatment targets for 
vascular risk factors as early on in the course of diabetes as possible. The American 
Diabetes Association (ADA) has recommended an HbA1c target of 7.0% as the target 
for good glycemic control, and in individual patients, a goal as close to normal (HbA1c 
 6.0%) without occurrence of hypoglycemia,4 while the American Association of 
Clinical Endocrinologists (AACE) has recommended an HbA1c goal of 6.5%.5 The 
primary lipid goal for people with diabetes recommended by the National Cholesterol 
Education Program is to achieve a LDL-C value of 100 mg/dL, and for very high-risk 
subjects of 70 mg/dL.6 Based on the most recent surveys a large proportion of subjects 
with type 2 diabetes are not at their HbA1c and LDL-C goals.7,8
It has become abundantly clear that as glycemic and lipid treatment goals have 
become more stringent, a requirement for early combination therapy is needed 
in many patients. While this is self-evident in severely hyperglycemic patients, it 
is not always appreciated that the absolute glucose-lowering efﬁ  cacy of a single 
oral antihyperglycemic agent is smaller in subjects who have milder degrees of 
hyperglycemia.9 Thus even in subjects with more modest degress of hyperglycemia, Diabetes, Metabolic Syndrome and Obesity 2009:2 12
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add-on treatment to monotherapy, usually metformin, is 
frequently required. This approach has been embodied in the 
recently published titration protocols developed by the ADA 
and the AACE for the treatment of hyperglycemia.10,11 Simi-
larly it is being increasingly appreciated that an LDL-C target 
of 70 mg/dL often requires 50% reduction in LDL-C 
levels, an effect that may not always be achieved with maxi-
mum doses of statin montherapy. Thus add-on treatment with 
secondary LDL-C-lowering agents is frequently required as 
well. These needs have stimulated drug development and this 
has led to the introduction of several new antihyperglycemic 
and LDL-C-lowering agents which will require long-term 
evaluation for safety and health efﬁ  cacy. It is in this con-
text that the recent introduction of a second generation bile 
sequestrant, colesevelam, as an antihyperglycemic agent with 
LDL-lowering properties needs to be appreciated.
Initial use of bile acid sequestrants 
as LDL-C-lowering agents
Colesevelam was ﬁ  rst introduced as an LDL-C-lowering 
drug in 2000. This followed the long-standing use of bile 
acid binding resins for treatment of hypercholesterolemia 
beginning almost 50 years ago.12 As their cholesterol-lowering 
properties were appreciated, the bile sequestrants became the 
initial choice for lowering of elevated LDL-C. The ﬁ  rst resin 
available was colestyramine, to be followed a few years later 
by colestipol. These are positively charged, non-absorbable, 
anion-exchange, long-chain polymers that bind the anionic 
bile acids, and in so doing disrupt the enterohepatic circulation 
of bile acids, depleting the bile acid pool by about 40%. 
Normally approximately 5% of the bile acid pool is lost 
daily in the stool, an amount that is replaced by new bile acid 
synthesis from hepatic cholesterol, initiated by the action of 
the rate limiting enzyme of bile acid synthesis, cholesterol 7α 
hydroxylase. This daily synthesis of bile acids accounts for a 
sizable portion of daily cholesterol turnover (about 50%) and 
is regulated through the action of the farnesoid X receptor 
(FXR) in the liver on cholesterol 7α hydroxylase. Bile acids 
are the primary ligand of FXR and inhibit its activity, leading 
to suppression of the hydroxylase. Thus bile acid seques-
tration will result in loss of FXR-mediated suppression of 
cholesterol 7α-hydroxylase, leading to a rise in its activity 
which diverts hepatic cholesterol to bile acid synthesis. The 
fall in hepatocyte cholesterol concentration then results in 
an upregulation of LDL receptors and a fall in circulating 
LDL-C levels. Cholestyramine in doses of 4 to 24 g13 and 
colestipol 2 to 16 g daily14 were shown to lower LDL-C in 
a dose-dependent manner by 5% to 28%, and in the case of 
colestipol, apo B was reduced in parallel by 2% to 28%.14 Both 
agents caused a modest increase in triglyceride levels.
A major barrier to the more widespread use of these 
two ﬁ  rst generation sequestrants is their unpalatable gritty 
consistency when the powder is ingested as a slurry with 
liquid. In addition constipation and ﬂ  atulence are common 
particularly with higher doses. The introduction of statins 
in the late 1980s, which were both more potent as well as 
more tolerable than bile acid sequestrants, quickly displaced 
these agents as ﬁ  rst choice treatment for lowering LDL-C. 
Despite this, the limitations of statin therapy in patients with 
severe hypercholesterolemia in whom a minimum of 50% 
LDL-C lowering was needed, were soon appreciated. Several 
studies were published in the early 1990s demonstrating the 
value of add-on cholestyramine or colestipol to treatment 
with, pravastatin,15 ﬂ  uvastatin16 and lovastatin,17 in which 
approximately 50% lowering of LDL-C and up to 40% 
lowering of apo B18 was achieved. Furthermore combina-
tion of these agents with non-statin drugs such as niacin19 
or ﬁ  brates20 provided added LDL-C-lowering capability to 
triglyceride-lowering or HDL-C-raising agents, without the 
safety concerns that had been raised by combined use of 
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Figure 1 The enterohepatic circulation of bile acids.
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these drugs with statins. The large body of published clinical 
trials data, the record of safety, the characterization of their 
adverse effects, and the decades-long experience with ﬁ  rst 
generation bile acid sequestrant therapy in the treatment of 
hypercholesterolemia21 are important factors in evaluating the 
place of colesevelam in the management of type 2 diabetes 
because of the similarities in pharmacology and mechanisms 
of action among all bile acid sequestrants.
Evidence that bile acid sequestrants 
prevent cardiovascular disease
In recent years concerns about the effects of antihyperglycemic 
agents on cardiovascular disease (CVD) are coming in to 
focus. The issue was initially raised by the University Group 
Diabetes Program which found that the biguanide phenformin 
and the sulfonylurea tolbutamide were associated with 
increased occurrence of cardiovascular disease.22 This led 
to the withdrawal of phenformin, and the requirement for 
a black box warning for all sulfonylurea and subsequently 
meglitinide drugs. There has been little subsequent evidence 
that sulfonylurea drugs increase CVD, and the remaining 
biguanide, metformin, in a single small study was associated 
with a reduced occurrence of myocardial infarction.23 
However a recent meta-analysis of clinical trials using 
rosiglitazone has once again raised concern that some antihy-
perglycemic agents may have deleterious effects on CVD.24 
Because CVD is of such importance in the prognosis of type 2 
diabetes, this issue has received great attention, such that 
the US Food and Drug Agency has recently recommended 
that long-term clinical trial assessments of effects of all new 
antihyperglycemia agents on CVD incidence will now be 
mandatory.25 This requirement is also probably necessary 
for all lipid-lowering agents used in long-term diabetes 
management, as has been recently highlighted by the ﬁ  nding 
that fenoﬁ  brate did not signiﬁ  cantly reduce the primary CVD 
outcome in a large population with type 2 diabetes.26
In this setting it is worth brieﬂ  y reviewing the available 
evidence that bile acid depletion therapy has beneﬁ  cial effects 
on CVD occurrence. The ﬁ  rst indication that lowering of 
LDL-C through biliary diversion could successfully reduce 
CVD events comes from the Program on the Surgical Con-
trol of the Hyperlipidemias (POSCH).27 In this study of 
838 men and woman with hypercholesterolemia who had 
survived a ﬁ  rst myocardial infarction, biliary diversion and 
LDL-C reduction was achieved by means of partial ileal 
bypass surgery. LDL-C levels were reduced by 37.7% 
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Figure 2 Comparison of the structures of cholestyramine and colesevelam.Diabetes, Metabolic Syndrome and Obesity 2009:2 14
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over a 5-year period compared to that in the control group 
and this was accompanied by a signiﬁ  cant 35% reduction 
in combined coronary heart disease (CHD) mortality and 
non-fatal myocardial infarction. In the modern context, this 
study is highly relevant because it constitutes clinical trial 
evidence supporting the contention that lowering of LDL-C 
can explain most if not all of the beneﬁ  cial effect on CVD 
in the long-term clinical trials with statins. The strongest 
evidence that the effects of surgically induced biliary diver-
sion are mirrored by sequestrant-induced biliary depletion 
comes from the Lipid Research Clinics Coronary Primary 
Prevention Trial (LRC-CPPT)13 and the NHLBI Type II 
Coronary Intervention Study.28 In the CPPT, one of the ﬁ  rst 
large studies to deﬁ  nitively associate a drug-induced reduc-
tion in LDL-C with a reduction in CHD risk, 3806 men 
were randomized to cholestyramine or placebo for a mean 
of 7.4 years; the cholestyramine group had a 19% reduction 
in CHD risk (p  0.05) that was associated with a 13% 
decrease in LDL-C levels.13 The NHLBI Type II Coronary 
Intervention Study28 evaluated the effects of cholestyramine 
versus placebo on the progression of coronary angiographic 
lesions after 5 years of treatment in 116 patients. LDL-C 
levels were reduced by 26% in the cholestyramine and 5% 
in the placebo groups (p  0.001) and coronary lesions 
progressed in 49% of placebo-treated patients versus 32% 
of cholestyramine-treated patients (p  0.05). There have 
also been several secondary intervention trials using bile 
acid sequestrants in combination with niacin, statins and/or 
ﬁ  brates which were uniformly and in some cases dramatically 
positive, but in which it was not possible to tease out the 
effect of the bile acid sequestrants from the other agents 
used.19,29,30 Finally a meta-analysis of 8 bile acid sequestrant 
studies found that monotherapy signiﬁ  cantly reduced cardiac 
mortality.31 While there have been no such intervention trials 
with colesevelam, the evidence to date supports the notion that 
lowering of LDL-C through bile acid depletion is associated 
with beneﬁ  cial effects on CHD.
Colesevelam as an LDL-C-
lowering agent
Although colesevelam acts in the same way as do chole-
styramine and colestipol it exhibits several important differ-
ences from them. First, colesevelam was developed to have 
enhanced speciﬁ  city, greater afﬁ  nity, and higher capacity for 
binding bile acids than cholestyramine or colestipol. This 
was achieved by engineering long hydrophobic side chains 
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to the backbone polymer, which maximize hydrophobic 
interactions with bile acids, adding to the effects of the 
ionic bonds that bind bile acids in the two ﬁ  rst generation 
compounds. Thus colesevelam is at least 2 to 3 times more 
potent on a weight basis than either cholestyramine or 
colestipol. Hence smaller amounts of colesevelam can be 
used effectively, with less adverse effects, and with greater 
tolerability through its packaging into tablets instead of 
a slurry of liquefied powder. Although the usual dose 
requires taking 6 to 7 tablets (625 mg/tablet) per day, this 
is still considerably more acceptable than the ingestion of 
an insoluble powder several times a day. Finally there is no 
need for titration of the dose of colesevelam to allow for 
tolerability, unlike that commonly required by ﬁ  rst genera-
tion sequestrants.
Monotherapy
The ﬁ  rst of the clinical trials with colesevelam evaluating 
its efficacy as an LDL-C-lowering agent, utilized a 
double-blind, placebo-controlled, dose ranging design (1.5, 
2.25, 3.0, or 3.75 g/day), conducted in 137 patients for 
6 weeks. Colesevelam lowered LDL-C levels signiﬁ  cantly 
and dose-dependently by up to 19%, increased HDL-C by 
up to 8% to 9% and no signiﬁ  cant changes were observed 
in triglyceride levels.32 Similar ﬁ  ndings were obtained in a 
24-week study which demonstrated that LDL-C reduction 
occurred within 2 weeks, was sustained over 6 months and 
was paralleled by up to a 12% reduction in apo B.33
Combination therapy with statins
Colesevelam has been studied in combination studies with 
small doses of lovastatin (10 mg), simvastatin (10 and 
20 mg), and atorvastatin (10 mg), in which LDL-C levels 
were lowered respectively by up to 34%, 42% and 48%.34–36 
Although it is usually recommended that the statin dose 
should be up-titrated before a second agent is added if greater 
LDL-C lowering is needed, actual or potential adverse statin 
effects may limit the dose that can be used, in which case 
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the addition of colesevelam signiﬁ  cantly adds to the effect 
of low dose statins.
Effects of colesevelam on other 
lipoproteins and lipoprotein 
subfractions
Bile sequestrants in general and colesevelam in particular 
appear to increase HDL-C and apo A-I levels modestly, 
perhaps through the deactivation of FXR, since FXR 
has been demonstrated to suppress apo A-I synthesis.37 
Cholestyramine and colestipol have been shown to raise 
triglyceride levels, and this constitutes a concern in patients 
with type 2 diabetes in whom hypertriglyceridemia is 
common. Fortunately the effect of bile acid sequestrants on 
triglyceride levels is usually mild, though it can be dramatic 
in severely hypertriglyceridemic subjects38 and this is a 
contraindication to the use of bile sequestrants. The increase 
in triglyceride levels was shown to result from increased 
VLDL production,39 an effect that has been partially linked 
to the reduction of FXR activity by bile acid depletion. Bile 
acids, acting through FXR and hepatocyte nuclear factor 4, 
have been shown to reduce microsomal triglyceride transfer 
protein which initiates VLDL assembly.40 Although there 
have been no formal reports of colesevelam exacerbating 
severe hypertriglyceridemia, this is almost certainly 
a class effect and the use of colesevelam in severely 
hypertriglyceridemic subjects is contraindicated. Mild to 
moderate elevation of triglyceride levels with colesevelam 
have been described.41 Despite this tendency to increase 
triglyceride levels, colesevelam has been demonstrated to 
increase LDL size42 while decreasing LDL particle num-
ber predominantly by reducing the number of small LDL 
particles in a manner unrelated to triglyceride levels.43 This 
may be due to suppression of hepatic lipase activity as a 
result of the bile-acid sequestrant-induced upregulation 
of FXR, since FXR has been demonstrated to suppress 
hepatic lipase.44 Further studies are needed to understand 
this interesting phenomenon.
Combination therapy with non-statin 
drugs
Combination of colesevelam with ezetimibe may be helpful 
in subjects intolerant to statin treatment or in subjects who 
can tolerate only minimal amounts of statin. Colesevelam 
and ezetimibe have different modes of action and therefore 
might be expected to have additive effects on LDL-C. This 
was conﬁ  rmed in several short-term studies in which the 
combined treatment lowered LDL-C by 30% to 40%.45,46 In 
combination with fenoﬁ  brate,47 colesevelam was shown to 
lower LDL-C (17%), beyond that achieved with a ﬁ  brate, 
while the presence of the ﬁ  brate assured that there would 
be net triglyceride reduction (32%). This approach with or 
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without added ezetimibe may be useful if there was a need 
to avoid or minimize statin therapy in subjects with mixed 
dyslipidemia.
Colesevelam, a new 
antihyperglycemic agent
The effect of bile sequestrants to lower glucose levels 
was ﬁ  rst noted in 1994 in a study of cholestyramine in 
treatment of dyslipidemia in type 2 diabetes.48 Several 
subsequent studies produced conﬂ  icting results, but the 
Glucose Lowering Effect of Welchol study (GLOWS) 
clearly demonstrated that colesevelam improved glycemia 
in 65 type 2 diabetic subjects inadequately controlled on 
oral antihyperglycemic agents and randomized to 3.75 g of 
colesevelam versus placebo for 12 weeks.49 Colesevelam 
treatment was associated with an HbA1c reduction of 
0.5% from a baseline value of 7.9% to 8.1% compared to 
placebo. In addition there was a reduction in those receiv-
ing colesevelam in fasting glucose at 4 and 8 weeks and 
postprandial glucose at 12 weeks, as well as fructosamine 
levels, from baseline compared to placebo. In subjects 
with a baseline HbA1c  8.0%, the difference between 
colesevelam and placebo treatment was reduced by 1.0%. 
These ﬁ  ndings in this pilot study led to the larger pivotal 
trials for the indication of the use of colesevelam for treat-
ment of hyperglycemia in type 2 diabetes.
The pivotal trials testing a glucose-
lowering indication for colesevelam
Three similarly designed, concurrent, prospective, multi-
center, randomized, placebo-controlled parallel-group lasting 
16 to 26 weeks were conducted between August 2004 and 
July 2006, testing the effects of colesevelam on glycemic 
and lipid measures in type 2 diabetic subjects inadequately 
controlled on sulfonylurea,50 metformin51 and insulin41 
treatments respectively. Since these are the only large-
scale clinical trials with the primary objective of assessing 
the antiglycemic properties of colesevelam in established 
type 2 diabetic subjects that have been published, they are 
discussed below in detail. The subjects enrolled had an 
HbA1c between 7.5% to 9.5%, and in the metformin and sul-
fonylurea studies were respectively on stable doses of either 
metformin or a sulfonylurea alone, or in combination with 
other oral antihyperglycemic agents; dipeptidyl protease IV 
inhibitor therapy was not included. In the insulin studies 
participants had to be taking insulin alone or in combination 
with oral agents. In all of the studies, individuals with an 
LDL-C  60 mg, a triglyceride level 500 mg/dL or with 
dysphagia, or swallowing or intestinal dysmotility disor-
ders were among those excluded. Subjects were withdrawn 
from the study if their HbA1c or fasting glucose at any visit 
exceeded 10% or 260 mg/dL respectively or they developed 
hypoglycemia. After a 2-week, single-blind run-in period, 
subjects were randomized 1:1 to colesevelam taken either 
as six 625 mg tablets once daily or twice daily (total 3.75 g) 
or matching placebo (according to the preferences of the 
study participant), added to their prestudy antihyperglycemic 
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treatment. In the metformin and sulfonylurea-based treatment 
studies, assessments were made at 6, 12, 16 and 26 weeks, 
whereas in the insulin-based studies, these were done at 4, 
8 and 16 weeks; all were analyzed with the last observation 
carried forward. The primary efﬁ  cacy parameter was the 
HbA1c change.
Effect of colesevelam in patients 
with inadequately controlled type 2 
diabetes on sulfonylurea-based therapy50
Of 461 randomized subjects, 166 and 141 completed the study 
in the colesevelam and placebo group respectively. Their 
mean age was 57 years, 53% to 56% were men, a quarter 
were Hispanic and 10% to 15% African American, mean 
BMI was 33 and mean HbA1c was 8.2% to 8.3%. About one 
third were on sulfonylurea monotherapy, and the remainder 
were receiving combination therapy with metformin or in 
about a quarter of these, with a thiazolidinedione. At week 
26 colesevelam treatment resulted in a signiﬁ  cant least 
squares mean HbA1c reduction of 0.54% (p  0.001) from 
baseline compared to the placebo group. Similar results 
were observed in the sulfonylurea monotherapy (–0.79%, 
p  0.001) and sulfonylurea combination therapy subgroups 
(–0.42%, p  0.001). In addition both fasting glucose and 
fructosamine levels were reduced, with fasting glucose 
signiﬁ  cantly below baseline at 6 weeks. There were more 
subjects in the colesevelam group with a glycemic control 
response – defined as achievement of either a HbA1c 
reduction of  0.7% or a  30 mg/dL fasting glucose reduc-
tion (47%) compared to the placebo group (32%). Eighteen 
subjects in the colesevelam group and 40 in the placebo group 
met discontinuation criteria. The LDL-C fell by a net 16.7% 
and the triglyceride level rose by a net 17.7% in the cole-
sevelam treated group; both were signiﬁ  cant changes. The 
most common drug-related adverse event was constipation 
(6.1% versus 2.6% in the placebo group) and 18 subjects in 
the colesevelam, versus 9 in the placebo group withdrew due 
to a drug-related adverse event. There was no excess of hypo-
glycemic events or weight gain in the treatment group.
Effect of colesevelam in patients 
with inadequately controlled type 2 
diabetes on metformin-based therapy51
In this study 316 subjects were randomized, of whom 222 
completed the study. Their baseline characteristics were 
very similar to those in the sulfonylurea-treatment based 
trials described above. About half were receiving metformin 
monotherapy, and of those on combination therapy over 
85% were taking sulfonylurea drugs, and just under a half 
were treated with thiazolidinediones. Compared to placebo, 
colesevelam reduced the HbA1c by 0.54% (p  0.001) 
at 26 weeks from a mean baseline HbA1c of 8.3%; the 
net reduction was 0.47% for the monotherapy subgroup 
and 0.62% in those receiving combination therapy, and 
for those with a baseline HbA1c  8.0% the net reduc-
tion was 0.6%. A signiﬁ  cant 20.8 mg/dL reduction in the 
fasting glucose value was noted at 6 weeks at which time 
fructosamine levels had also been signiﬁ  cantly lowered; 
both remained signiﬁ  cantly lowered compared to placebo 
at 26 weeks. As in the sulfonylurea studies, a greater 
proportion of the colesevelam group achieved either a 
reduction in the HbA1c of  0.07% or fasting glucose 
 30 mg/dL than placebo (48% versus 35%), and only 
3 subjects in the colesevelam group met discontinuation 
criteria for hyperglycemia (or hypoglycemia) versus 16 in 
the placebo group. LDL-C levels fell by a signiﬁ  cant net 
15.9% from a baseline value of 99–106 mg/dL, apo B by 
8% (p  0.001) and triglyceride concentrations increased 
from a baseline value of 166 to 172 mg/dL by a net 4.7% 
in the colesevelam group at week 26 (39%–48% were on 
statin treatment). The adverse event experience paralleled 
that in the sulfonylurea study.
Effect of colesevelam in patients 
with inadequately controlled type 2 
diabetes on insulin-based therapy41
Of 287 insulin-treated patients randomized, 231 completed 
the study. Demographic characteristics of participants were 
very similar to those in the above two studies, although they 
were slightly more obese (mean BMI 35) and their mean 
total daily insulin dose was 74 to 78 units. Insulin therapy 
consisted of either basal insulin alone, insulin mixtures or true 
basal/bolus therapy, and about 40% were on insulin mono-
therapy. Over half of those on insulin/oral agent combination 
treatment received metformin, about a third of these subjects 
were treated with sulfonylurea, and just under a third were on 
a thiazolidinedione. The net treatment difference in HbA1c 
level from baseline to week 16 in the colesevelam group 
was –0.50% versus the placebo (p  0.001); the effects 
were similar in those on insulin monotherapy (–0.59%) 
versus those treated with insulin/oral agent combinations 
(–0.44%) and were greater in those with a baseline HbA1c 
 8.0% versus 8.0% (–0.57% compared to –0.38%). As 
in the previous studies, fasting glucose and fructosamine 
fell rapidly and were signiﬁ  cantly reduced compared to Diabetes, Metabolic Syndrome and Obesity 2009:2 19
Colesevelam, a dual antihyperglycemic, LDL-C-lowering agent
placebo within 4 weeks, and there were more subjects with 
a glycemic control response in the colesevelam group (49%) 
versus placebo (32%). In this study discontinuations for 
hyperglycemia were similar in the two groups. The LDL-C 
was reduced by a net 12.8% (p  0.001), apo B by a net 
5.3% (p  0.04) and triglyceride values increased by 21.5% 
(baseline triglyceride 155–167 mg/dL, p  0.001). In the 
colesevelam-treated group, the most frequently reported 
drug-related adverse events were constipation (6.8%), 
dyspepsia (3.4%), hypoglycemia (3.4%), ﬂ  atulence (2.0%), 
and nausea (1.4%), whereas in the placebo group, the most 
frequently reported adverse event was hypoglycemia (5.7%). 
Five subjects in the colesevelam group withdrew because of 
a drug related adverse effect versus 2 in the placebo group 
and there was no weight gain in either group.
Effects on insulin sensitivity 
and inﬂ  ammatory biomarkers
No signiﬁ  cant changes were noted in fasting insulin level or 
HOMA-IR in the metformin study51 nor on fasting C-peptide 
levels in any of the studies as a result of colesevelam treat-
ment. However high sensitivity CRP levels fell by 14.0% 
from baseline at 24 weeks in the colesevelam groups in 
both the sulfonylurea and metformin studies, and by 19% 
compared to placebo in a study of patients with mild hyper-
cholesterolemia.52 There was no effect on adiponectin levels 
with colesevelam treatment.51
Interactions with other drugs
Although bile sequestrants are not absorbed and therefore 
will not inﬂ  uence hepatic metabolism of other drugs, they 
are positively charged resins and tend to bind to acidic drugs, 
interfering with their absorption. This effect is greatest with 
cholestyramine, less with colestipol and least with cole-
sevelam. For example, no signiﬁ  cant effects of colesevelam 
administration were found on the pharmocokinetics of six 
drugs with narrow therapeutic indices, whose absorption is 
interfered with by cholestyramine, namely valproic acid, 
digoxin, quinidine, verapamil, metoprolol and warfarin.53 
Furthermore no effects of coadministration of colesevelam 
on drug levels of lovastatin, fenoﬁ  brate, metformin, glipizide, 
repaglinide and pioglitazone have been found.54 Colesevelam 
does interfere with absorption of glyburide, levothyroxine, 
oral contraceptives, and post-marketing reports suggest 
interactions with the therapeutic efﬁ  cacy of phenytoin and 
warfarin. It is recommended that coadministration of cole-
sevelam with drugs with narrow therapeutic indices, and 
fat-soluble vitamins be avoided;54 instead the administration 
of the sequestrant should be delayed by at least 4 hours after 
these medications are ingested.
Perspectives on the utility of colesevelam 
as an antihyperglycemic agent in type 2 
diabetes
The three pivotal studies demonstrate that add-on cole-
sevelam lowers the HbA1c by about 0.5% in subjects with an 
average HbA1c of approximately 8.2% to 8.3%, irrespective 
of whether the underlying treatment is metformin-, sulfo-
nylurea-, or insulin-based. These ﬁ  ndings suggest that the 
antihyperglycemic effect of colesevelam is independent of 
the nature of the medication to which it is added. This would 
further imply that the mechanism of the antihyperglycemic 
effect of colesevelam is additive to those of metformin or 
sulfonylureas and does not appear to enhance insulin action 
based on surrogate markers, although more deﬁ  nitive stud-
ies are needed to examine this question. The mechanism 
by which bile sequestrants in general and colesevelam in 
particular improve hyperglycemia is unknown. Sequestrants 
may interfere with intestinal glucose absorption,55 potentially 
enhance insulin release,56 and experimentally through the 
reduction of FXR activity, alter hepatic glucose metabolism, 
although studies have yielded conﬂ  icting results.57 Based 
on effects of colesevelam treatment on fasting glucose and 
fructosamine levels, its antihyperglycemic effect is complete 
within 4 weeks.
Colesevelam offers several advantages in subjects on oral 
antihyperglycemic therapy or insulin treatment whose HbA1c 
and/or LDL-C are mildly or moderately elevated above their 
targets. First this treatment simultaneously lowered HbA1c 
and LDL-C toward therapeutic targets without causing 
weight gain or excessive hypoglycemia in the clinical trials. 
Second, this class of non-absorbable resins offers a good 
safety record. Thirdly both surgical and pharmacologic 
biliary diversion to lower LDL-C has been shown to reduce 
coronary atherosclerosis and coronary heart disease events. 
Dividing the dose into 3 tablets at the midday meal and 3 
at the evening meal may offer the most convenient way to 
administer this relatively bulky medication. This regimen 
also avoids interactions with most other medications which 
are usually taken in the morning, since their absorption should 
be complete by the midday meal. Finally in an era where 
prevention of diabetes has been accepted as an important 
approach to ameliorating the epidemic of diabetes including 
the early initiation of pharmacotherapy in high risk predia-
betic individuals,58 colesevelam would seem to offer several 
advantages, for the reasons discussed above.Diabetes, Metabolic Syndrome and Obesity 2009:2 20
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